25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Infant Bacterial Therapeutics AB (publ)
Buy, Hold or Sell?

Let's analyze Infant Bacterial Therapeutics AB (publ) together

I guess you are interested in Infant Bacterial Therapeutics AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Infant Bacterial Therapeutics AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Infant Bacterial Therapeutics AB (publ)

I send you an email if I find something interesting about Infant Bacterial Therapeutics AB (publ).

1. Quick Overview

1.1. Quick analysis of Infant Bacterial Therapeutics AB (publ) (30 sec.)










1.2. What can you expect buying and holding a share of Infant Bacterial Therapeutics AB (publ)? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr12.64
Expected worth in 1 year
kr2.63
How sure are you?
23.7%

+ What do you gain per year?

Total Gains per Share
kr-10.01
Return On Investment
-24.7%

For what price can you sell your share?

Current Price per Share
kr40.60
Expected price per share
kr34.00 - kr46.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Infant Bacterial Therapeutics AB (publ) (5 min.)




Live pricePrice per Share (EOD)
kr40.60
Intrinsic Value Per Share
kr-55.39 - kr-63.33
Total Value Per Share
kr-42.76 - kr-50.70

2.2. Growth of Infant Bacterial Therapeutics AB (publ) (5 min.)




Is Infant Bacterial Therapeutics AB (publ) growing?

Current yearPrevious yearGrowGrow %
How rich?$15.9m$29m-$8.2m-39.7%

How much money is Infant Bacterial Therapeutics AB (publ) making?

Current yearPrevious yearGrowGrow %
Making money-$3.2m-$2.8m-$323.4k-10.1%
Net Profit Margin-139,075.0%-55,273.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Infant Bacterial Therapeutics AB (publ) (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#536 / 925

Most Revenue
#770 / 925

Most Profit
#349 / 925

Most Efficient
#914 / 925
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Infant Bacterial Therapeutics AB (publ)?

Welcome investor! Infant Bacterial Therapeutics AB (publ)'s management wants to use your money to grow the business. In return you get a share of Infant Bacterial Therapeutics AB (publ).

First you should know what it really means to hold a share of Infant Bacterial Therapeutics AB (publ). And how you can make/lose money.

Speculation

The Price per Share of Infant Bacterial Therapeutics AB (publ) is kr40.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Infant Bacterial Therapeutics AB (publ).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Infant Bacterial Therapeutics AB (publ), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr12.64. Based on the TTM, the Book Value Change Per Share is kr-2.50 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.71 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Infant Bacterial Therapeutics AB (publ).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.23-0.6%-0.24-0.6%-0.22-0.5%-0.16-0.4%-0.11-0.3%
Usd Book Value Change Per Share-0.23-0.6%-0.23-0.6%-0.07-0.2%-0.12-0.3%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.23-0.6%-0.23-0.6%-0.07-0.2%-0.12-0.3%0.030.1%
Usd Price Per Share5.01-6.17-6.18-7.40-8.62-
Price to Earnings Ratio-5.35--6.53--7.06--184.63--116.62-
Price-to-Total Gains Ratio-21.39--26.51--14.90--803.64--539.68-
Price to Book Ratio4.24-3.96-2.81-2.97-4.33-
Price-to-Total Gains Ratio-21.39--26.51--14.90--803.64--539.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.7961
Number of shares263
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.23-0.12
Usd Total Gains Per Share-0.23-0.12
Gains per Quarter (263 shares)-61.56-32.67
Gains per Year (263 shares)-246.23-130.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-246-2560-131-141
20-492-5020-261-272
30-739-7480-392-403
40-985-9940-523-534
50-1231-12400-653-665
60-1477-14860-784-796
70-1724-17320-915-927
80-1970-19780-1045-1058
90-2216-22240-1176-1189
100-2462-24700-1307-1320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%6.032.00.015.8%6.032.00.015.8%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%9.026.03.023.7%9.026.03.023.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.038.00.0%0.00.038.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%9.026.03.023.7%9.026.03.023.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Infant Bacterial Therapeutics AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.506-2.5030%-0.707-72%-1.328-47%0.333-854%
Book Value Per Share--12.63916.485-23%23.465-46%27.265-54%25.429-50%
Current Ratio--3.3284.850-31%9.576-65%21.550-85%30.502-89%
Debt To Asset Ratio--0.2890.211+37%0.106+172%0.087+234%0.065+344%
Debt To Equity Ratio--0.4070.273+49%0.119+241%0.103+296%0.075+442%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--652765112.0001032223970.000-37%1166684314.550-44%1362723986.410-52%1587866820.394-59%
Eps---2.506-2.541+1%-2.321-7%-1.673-33%-1.186-53%
Ev To Ebitda Ratio--infinfnan%-9.569nan%infnan%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.621-2.258+264%-1.910+208%-1.601+158%-1.228+98%
Free Cash Flow To Equity Per Share---0.621-2.221+258%-0.096-85%-1.195+93%0.356-274%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.995+1%
Intrinsic Value_10Y_max---63.334--------
Intrinsic Value_10Y_min---55.394--------
Intrinsic Value_1Y_max---7.562--------
Intrinsic Value_1Y_min---7.428--------
Intrinsic Value_3Y_max---21.794--------
Intrinsic Value_3Y_min---20.825--------
Intrinsic Value_5Y_max---34.909--------
Intrinsic Value_5Y_min---32.482--------
Market Cap528534860.000-37%722068112.000889113720.000-19%877650064.550-18%1039341536.410-31%1205530014.057-40%
Net Profit Margin----1390.7500%-552.7330%-608.0020%-332.3640%
Operating Margin----1390.7000%-552.7560%-611.5080%-338.5510%
Operating Ratio---1489.850-100%598.942-100%644.186-100%351.613-100%
Pb Ratio3.212-32%4.2413.963+7%2.813+51%2.966+43%4.330-2%
Pe Ratio-4.050+24%-5.346-6.533+22%-7.062+32%-184.627+3353%-116.618+2081%
Price Per Share40.600-32%53.60066.000-19%66.100-19%79.115-32%92.224-42%
Price To Free Cash Flow Ratio-16.356+24%-21.593-10.824-50%-8.934-59%-18.616-14%-44.945+108%
Price To Total Gains Ratio-16.198+24%-21.385-26.512+24%-14.900-30%-803.636+3658%-539.676+2424%
Quick Ratio---3.990-100%9.545-100%21.061-100%29.835-100%
Return On Assets---0.141-0.125-11%-0.089-37%-0.065-54%-0.053-63%
Return On Equity---0.198-0.160-19%-0.100-50%-0.075-62%-0.059-70%
Total Gains Per Share---2.506-2.5030%-0.707-72%-1.328-47%0.333-854%
Usd Book Value--15919590.50020764199.500-23%29016930.250-45%33418045.375-52%31074021.289-49%
Usd Book Value Change Per Share---0.234-0.2340%-0.066-72%-0.124-47%0.031-854%
Usd Book Value Per Share--1.1821.541-23%2.194-46%2.549-54%2.378-50%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--61033537.97296512941.195-37%109084983.410-44%127414692.729-52%148465547.707-59%
Usd Eps---0.234-0.238+1%-0.217-7%-0.156-33%-0.111-53%
Usd Free Cash Flow---781660.000-2844620.625+264%-2365994.125+203%-1976225.350+153%-1509023.566+93%
Usd Free Cash Flow Per Share---0.058-0.211+264%-0.179+208%-0.150+158%-0.115+98%
Usd Free Cash Flow To Equity Per Share---0.058-0.208+258%-0.009-85%-0.112+93%0.033-274%
Usd Market Cap49418009.410-37%67513368.47283132132.820-19%82060281.035-18%97178433.654-31%112717056.314-40%
Usd Price Per Share3.796-32%5.0126.171-19%6.180-19%7.397-32%8.623-42%
Usd Profit---3157027.500-3200154.375+1%-2876691.125-9%-2066130.275-35%-1459630.961-54%
Usd Revenue---116.875-100%1799.875-100%425.425-100%1208.118-100%
Usd Total Gains Per Share---0.234-0.2340%-0.066-72%-0.124-47%0.031-854%
 EOD+3 -5MRQTTM+12 -21YOY+6 -275Y+9 -2410Y+8 -26

3.3 Fundamental Score

Let's check the fundamental score of Infant Bacterial Therapeutics AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.050
Price to Book Ratio (EOD)Between0-13.212
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than13.328
Debt to Asset Ratio (MRQ)Less than10.289
Debt to Equity Ratio (MRQ)Less than10.407
Return on Equity (MRQ)Greater than0.15-0.198
Return on Assets (MRQ)Greater than0.05-0.141
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Infant Bacterial Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.144
Ma 20Greater thanMa 5041.935
Ma 50Greater thanMa 10047.250
Ma 100Greater thanMa 20041.540
OpenGreater thanClose41.800
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Infant Bacterial Therapeutics AB (publ)

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2025-02-17 11:05:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Infant Bacterial Therapeutics AB (publ) earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-139,075.0%+139,075.0%
TTM-139,075.0%YOY-55,273.3%-83,801.7%
TTM-139,075.0%5Y-60,800.2%-78,274.8%
5Y-60,800.2%10Y-33,236.4%-27,563.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--100.3%+100.3%
TTM-139,075.0%-211.5%-138,863.5%
YOY-55,273.3%-213.8%-55,059.5%
5Y-60,800.2%-346.2%-60,454.0%
10Y-33,236.4%-489.2%-32,747.2%
4.3.1.2. Return on Assets

Shows how efficient Infant Bacterial Therapeutics AB (publ) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • -14.1% Return on Assets means that Infant Bacterial Therapeutics AB (publ) generated kr-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is -14.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.1%TTM-12.5%-1.6%
TTM-12.5%YOY-8.9%-3.7%
TTM-12.5%5Y-6.5%-6.1%
5Y-6.5%10Y-5.3%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.1%-12.0%-2.1%
TTM-12.5%-12.1%-0.4%
YOY-8.9%-11.4%+2.5%
5Y-6.5%-12.8%+6.3%
10Y-5.3%-14.6%+9.3%
4.3.1.3. Return on Equity

Shows how efficient Infant Bacterial Therapeutics AB (publ) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • -19.8% Return on Equity means Infant Bacterial Therapeutics AB (publ) generated kr-0.20 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is -19.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.8%TTM-16.0%-3.9%
TTM-16.0%YOY-10.0%-6.0%
TTM-16.0%5Y-7.5%-8.5%
5Y-7.5%10Y-5.9%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.8%-15.4%-4.4%
TTM-16.0%-16.2%+0.2%
YOY-10.0%-14.7%+4.7%
5Y-7.5%-18.6%+11.1%
10Y-5.9%-19.5%+13.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Infant Bacterial Therapeutics AB (publ).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Infant Bacterial Therapeutics AB (publ) is operating .

  • Measures how much profit Infant Bacterial Therapeutics AB (publ) makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-139,070.0%+139,070.0%
TTM-139,070.0%YOY-55,275.6%-83,794.4%
TTM-139,070.0%5Y-61,150.8%-77,919.2%
5Y-61,150.8%10Y-33,855.1%-27,295.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.5%+201.5%
TTM-139,070.0%-313.4%-138,756.6%
YOY-55,275.6%-215.2%-55,060.4%
5Y-61,150.8%-371.8%-60,779.0%
10Y-33,855.1%-492.1%-33,363.0%
4.3.2.2. Operating Ratio

Measures how efficient Infant Bacterial Therapeutics AB (publ) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1,489.850-1,489.850
TTM1,489.850YOY598.942+890.908
TTM1,489.8505Y644.186+845.664
5Y644.18610Y351.613+292.573
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.139-2.139
TTM1,489.8503.198+1,486.652
YOY598.9423.358+595.584
5Y644.1864.842+639.344
10Y351.6136.500+345.113
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Infant Bacterial Therapeutics AB (publ).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Infant Bacterial Therapeutics AB (publ) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.33 means the company has kr3.33 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 3.328. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.850. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.328TTM4.850-1.522
TTM4.850YOY9.576-4.727
TTM4.8505Y21.550-16.701
5Y21.55010Y30.502-8.951
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3283.610-0.282
TTM4.8503.871+0.979
YOY9.5764.609+4.967
5Y21.5505.977+15.573
10Y30.5026.216+24.286
4.4.3.2. Quick Ratio

Measures if Infant Bacterial Therapeutics AB (publ) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off kr0.00 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.990-3.990
TTM3.990YOY9.545-5.555
TTM3.9905Y21.061-17.071
5Y21.06110Y29.835-8.774
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.085-3.085
TTM3.9903.360+0.630
YOY9.5454.400+5.145
5Y21.0615.972+15.089
10Y29.8356.483+23.352
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Infant Bacterial Therapeutics AB (publ).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Infant Bacterial Therapeutics AB (publ) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that Infant Bacterial Therapeutics AB (publ) assets are financed with 28.9% credit (debt) and the remaining percentage (100% - 28.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.289. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.211. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.289TTM0.211+0.078
TTM0.211YOY0.106+0.105
TTM0.2115Y0.087+0.124
5Y0.08710Y0.065+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2890.341-0.052
TTM0.2110.343-0.132
YOY0.1060.315-0.209
5Y0.0870.363-0.276
10Y0.0650.384-0.319
4.5.4.2. Debt to Equity Ratio

Measures if Infant Bacterial Therapeutics AB (publ) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A Debt to Equity ratio of 40.7% means that company has kr0.41 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.407. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.273. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.407TTM0.273+0.134
TTM0.273YOY0.119+0.153
TTM0.2735Y0.103+0.170
5Y0.10310Y0.075+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4070.386+0.021
TTM0.2730.429-0.156
YOY0.1190.391-0.272
5Y0.1030.450-0.347
10Y0.0750.495-0.420
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Infant Bacterial Therapeutics AB (publ) generates.

  • Above 15 is considered overpriced but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A PE ratio of -5.35 means the investor is paying kr-5.35 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The EOD is -4.050. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.346. Based on the earnings, the company is expensive. -2
  • The TTM is -6.533. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.050MRQ-5.346+1.297
MRQ-5.346TTM-6.533+1.187
TTM-6.533YOY-7.062+0.529
TTM-6.5335Y-184.627+178.093
5Y-184.62710Y-116.618-68.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.050-2.247-1.803
MRQ-5.346-2.706-2.640
TTM-6.533-3.253-3.280
YOY-7.062-3.392-3.670
5Y-184.627-6.132-178.495
10Y-116.618-6.735-109.883
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The EOD is -16.356. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -21.593. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.824. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.356MRQ-21.593+5.237
MRQ-21.593TTM-10.824-10.769
TTM-10.824YOY-8.934-1.890
TTM-10.8245Y-18.616+7.792
5Y-18.61610Y-44.945+26.329
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.356-3.026-13.330
MRQ-21.593-3.582-18.011
TTM-10.824-3.816-7.008
YOY-8.934-4.463-4.471
5Y-18.616-8.265-10.351
10Y-44.945-9.266-35.679
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Infant Bacterial Therapeutics AB (publ) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.24 means the investor is paying kr4.24 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The EOD is 3.212. Based on the equity, the company is fair priced.
  • The MRQ is 4.241. Based on the equity, the company is fair priced.
  • The TTM is 3.963. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.212MRQ4.241-1.029
MRQ4.241TTM3.963+0.278
TTM3.963YOY2.813+1.150
TTM3.9635Y2.966+0.997
5Y2.96610Y4.330-1.363
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2121.948+1.264
MRQ4.2412.223+2.018
TTM3.9632.427+1.536
YOY2.8132.469+0.344
5Y2.9663.767-0.801
10Y4.3304.507-0.177
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets239,566
Total Liabilities69,303
Total Stockholder Equity170,263
 As reported
Total Liabilities 69,303
Total Stockholder Equity+ 170,263
Total Assets = 239,566

Assets

Total Assets239,566
Total Current Assets230,610
Long-term Assets8,956
Total Current Assets
Cash And Cash Equivalents 223,388
Other Current Assets 1
Total Current Assets  (as reported)230,610
Total Current Assets  (calculated)223,389
+/- 7,221
Long-term Assets
Intangible Assets 8,886
Long-term Assets  (as reported)8,956
Long-term Assets  (calculated)8,886
+/- 70

Liabilities & Shareholders' Equity

Total Current Liabilities69,303
Long-term Liabilities0
Total Stockholder Equity170,263
Total Current Liabilities
Accounts payable 46,993
Other Current Liabilities 420
Total Current Liabilities  (as reported)69,303
Total Current Liabilities  (calculated)47,413
+/- 21,890
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)170,263
Total Stockholder Equity (calculated)0
+/- 170,263
Other
Capital Stock3,672
Common Stock Shares Outstanding 13,471
Net Invested Capital 170,263
Net Working Capital 161,307



6.2. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
> Total Assets 
0
0
82,543
82,543
0
133,127
0
110,109
100,925
92,224
83,006
175,024
597,313
600,420
589,820
563,371
561,035
554,977
545,348
518,273
523,168
492,620
480,304
450,318
451,138
429,414
421,452
408,478
409,967
400,007
396,361
349,619
333,694
317,390
386,715
351,334
348,878
296,444
239,303
239,566
239,566239,303296,444348,878351,334386,715317,390333,694349,619396,361400,007409,967408,478421,452429,414451,138450,318480,304492,620523,168518,273545,348554,977561,035563,371589,820600,420597,313175,02483,00692,224100,925110,1090133,127082,54382,54300
   > Total Current Assets 
1,054
0
66,318
66,318
44,411
116,902
0
94,695
85,715
77,168
68,154
160,376
582,869
586,180
575,784
549,539
547,407
541,553
532,128
505,257
510,356
480,012
467,900
438,118
439,142
417,622
409,864
397,094
398,767
389,011
385,569
339,031
323,310
307,210
376,739
341,562
339,310
287,080
230,143
230,610
230,610230,143287,080339,310341,562376,739307,210323,310339,031385,569389,011398,767397,094409,864417,622439,142438,118467,900480,012510,356505,257532,128541,553547,407549,539575,784586,180582,869160,37668,15477,16885,71594,6950116,90244,41166,31866,31801,054
       Cash And Cash Equivalents 
-1,054
0
44,411
44,411
-44,411
116,384
0
93,786
84,673
76,323
67,176
158,274
581,081
576,800
566,786
542,170
540,514
539,453
511,888
495,188
500,995
473,608
463,043
423,438
425,758
409,066
390,360
386,752
382,179
373,976
368,331
335,840
306,680
300,953
367,207
329,064
309,618
272,510
226,196
223,388
223,388226,196272,510309,618329,064367,207300,953306,680335,840368,331373,976382,179386,752390,360409,066425,758423,438463,043473,608500,995495,188511,888539,453540,514542,170566,786576,800581,081158,27467,17676,32384,67393,7860116,384-44,41144,41144,4110-1,054
       Short-term Investments 
2,109
0
0
0
88,822
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000088,8220002,109
       Net Receivables 
0
0
0
0
0
0
0
53
49
0
0
0
0
0
0
0
0
0
665
713
1,587
910
1,627
1,955
77
8,556
2,857
10,342
1,134
15,035
17,239
1,778
16,630
6,257
9,532
6,736
29,692
14,570
0
0
0014,57029,6926,7369,5326,25716,6301,77817,23915,0351,13410,3422,8578,556771,9551,6279101,58771366500000000049530000000
       Other Current Assets 
0
0
21,907
21,907
0
518
0
856
993
845
978
2,102
1,788
9,380
8,998
7,369
6,893
2,100
20,240
10,069
9,361
6,404
4,857
14,680
13,307
8,556
19,504
10,342
16,588
15,035
17,238
3,191
16,630
6,257
9,532
5,762
29,692
14,570
3,947
1
13,94714,57029,6925,7629,5326,25716,6303,19117,23815,03516,58810,34219,5048,55613,30714,6804,8576,4049,36110,06920,2402,1006,8937,3698,9989,3801,7882,1029788459938560518021,90721,90700
   > Long-term Assets 
-1,054
0
16,225
16,225
-44,411
16,225
0
15,414
15,210
15,056
14,852
14,648
14,444
14,240
14,036
13,832
13,628
13,424
13,220
13,016
12,812
12,608
12,404
12,200
11,996
11,792
11,588
11,384
11,200
10,996
10,792
10,588
10,384
10,180
9,976
9,772
9,568
9,364
9,160
8,956
8,9569,1609,3649,5689,7729,97610,18010,38410,58810,79210,99611,20011,38411,58811,79211,99612,20012,40412,60812,81213,01613,22013,42413,62813,83214,03614,24014,44414,64814,85215,05615,21015,414016,225-44,41116,22516,2250-1,054
       Intangible Assets 
0
0
0
0
0
0
0
15,414
0
15,006
14,802
14,598
14,394
14,190
13,986
13,782
13,578
13,374
13,170
12,966
12,762
12,558
12,354
12,150
11,946
11,742
11,538
11,334
11,130
10,926
10,722
10,518
10,314
10,110
9,906
9,702
9,498
9,294
9,090
8,886
8,8869,0909,2949,4989,7029,90610,11010,31410,51810,72210,92611,13011,33411,53811,74211,94612,15012,35412,55812,76212,96613,17013,37413,57813,78213,98614,19014,39414,59814,80215,006015,4140000000
       Long-term Assets Other 
-1,054
0
16,225
16,225
-44,411
16,225
0
0
15,210
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
70
70
70
70
70
70
70
0
70
70
70
0
07070700707070707070705050505050505050505050505050505050505015,2100016,225-44,41116,22516,2250-1,054
> Total Liabilities 
0
0
7,734
7,734
0
6,079
0
4,883
4,262
8,625
3,993
6,653
8,161
10,603
8,960
6,654
5,005
6,507
7,417
7,876
11,593
8,965
15,249
10,164
10,446
17,886
9,980
13,224
33,914
20,402
24,539
17,913
24,456
36,462
40,669
46,180
71,538
59,767
35,275
69,303
69,30335,27559,76771,53846,18040,66936,46224,45617,91324,53920,40233,91413,2249,98017,88610,44610,16415,2498,96511,5937,8767,4176,5075,0056,6548,96010,6038,1616,6533,9938,6254,2624,88306,07907,7347,73400
   > Total Current Liabilities 
0
0
7,734
7,734
0
6,079
0
4,883
4,262
8,625
3,993
6,653
8,161
10,603
8,960
6,654
5,005
6,507
7,417
7,876
11,593
8,965
15,249
10,164
10,446
17,886
9,980
13,224
33,914
20,402
24,540
17,913
24,457
36,462
40,669
46,180
71,539
59,766
35,276
69,303
69,30335,27659,76671,53946,18040,66936,46224,45717,91324,54020,40233,91413,2249,98017,88610,44610,16415,2498,96511,5937,8767,4176,5075,0056,6548,96010,6038,1616,6533,9938,6254,2624,88306,07907,7347,73400
       Accounts payable 
0
0
518
518
0
269
0
1,116
1,915
1,150
668
506
1,326
1,083
5,543
3,507
910
2,432
2,809
943
1,385
208
7,339
1,232
3,400
5,985
5,180
4,797
19,843
6,535
6,449
8,746
7,145
18,324
25,543
30,067
41,364
45,120
12,097
46,993
46,99312,09745,12041,36430,06725,54318,3247,1458,7466,4496,53519,8434,7975,1805,9853,4001,2327,3392081,3859432,8092,4329103,5075,5431,0831,3265066681,1501,9151,1160269051851800
       Other Current Liabilities 
0
0
7,216
7,216
0
5,810
0
3,767
2,347
7,475
3,325
6,147
6,835
9,520
3,417
3,147
4,095
4,075
4,608
6,933
10,208
8,757
7,910
8,932
7,046
11,901
4,800
8,427
14,071
13,867
18,091
9,167
17,312
18,138
15,126
16,113
30,175
14,646
23,179
420
42023,17914,64630,17516,11315,12618,13817,3129,16718,09113,86714,0718,4274,80011,9017,0468,9327,9108,75710,2086,9334,6084,0754,0953,1473,4179,5206,8356,1473,3257,4752,3473,76705,81007,2167,21600
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,797
19,843
6,535
-1
8,746
-1
0
0
1
-1
1
-1
0
0-11-1100-18,746-16,53519,8434,797000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
-1
0
0
0
0
0
0
000000-1010000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,578
0
13,170
12,966
12,762
12,558
12,354
12,150
11,946
11,742
11,538
11,334
11,130
10,926
10,722
10,518
0
10,110
0
0
0
0
0
0
00000010,110010,51810,72210,92611,13011,33411,53811,74211,94612,15012,35412,55812,76212,96613,170013,5780000000000000000
> Total Stockholder Equity
11,031
0
74,809
74,809
74,809
127,048
0
105,226
96,663
83,599
79,013
168,371
589,152
589,817
580,860
556,717
556,030
548,470
537,931
510,397
511,575
483,655
465,055
440,154
440,692
411,528
411,472
395,254
376,053
379,605
371,822
331,706
309,238
280,928
346,046
305,154
277,340
236,677
204,028
170,263
170,263204,028236,677277,340305,154346,046280,928309,238331,706371,822379,605376,053395,254411,472411,528440,692440,154465,055483,655511,575510,397537,931548,470556,030556,717580,860589,817589,152168,37179,01383,59996,663105,2260127,04874,80974,80974,809011,031
   Common Stock
0
0
500
500
0
1,500
0
1,500
1,500
1,500
1,500
1,800
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,672
3,672
3,672
3,672
3,672
0
03,6723,6723,6723,6723,6723,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0601,8001,5001,5001,5001,50001,500050050000
   Retained Earnings Total Equity0000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
11,031
0
0
0
74,809
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
672,078
0
0
0
0
0
-1
-1
0
0
0
1
-1
-2
0
0
00-2-11000-1-100000672,078000000000000000000074,80900011,031
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
667,167
667,167
667,184
667,184
668,931
669,018
669,019
669,022
669,022
669,022
670,926
670,926
670,926
670,926
671,436
0
0
0
0
0
0
000000671,436670,926670,926670,926670,926669,022669,022669,022669,019669,018668,931667,184667,184667,167667,1670000000000000000000
   Treasury Stock0000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
52,350
52,350
0
140,473
0
140,473
140,473
141,357
141,357
239,474
668,139
668,139
667,167
667,167
667,167
667,167
667,167
667,167
667,167
667,184
667,184
668,931
669,018
669,019
669,022
669,022
669,022
670,926
670,924
670,925
670,926
671,436
766,829
766,828
766,827
768,838
768,842
0
0768,842768,838766,827766,828766,829671,436670,926670,925670,924670,926669,022669,022669,022669,019669,018668,931667,184667,184667,167667,167667,167667,167667,167667,167667,167668,139668,139239,474141,357141,357140,473140,4730140,473052,35052,35000



6.3. Balance Sheets

Currency in SEK. All numbers in thousands.




6.4. Cash Flows

Currency in SEK. All numbers in thousands.




6.5. Income Statements

Currency in SEK. All numbers in thousands.